Recognition of carcinoembryonic antigen peptide and heteroclitic peptide by peripheral blood T lymphocytes

Journal of Immunotherapy

Volumn 30, Issue 3, 2007, Pages 350-358

  Brown, Matthew E ^a   Miao, Haixi ^a   McKee, Mark D ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b MC 7118 ^*  (United States)

Author keywords

Carcinoembryonic antigen; Heteroclitic antigen; T cell; T cell avidity

Indexed keywords

ALANYLLEUCYLSERYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; CARCINOEMBRYONIC ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 7; PEPTIDE; TYROSYLALANYLSERYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; TYROSYLLEUCYLALANYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; TYROSYLLEUCYLSERYLGLYCYLALANYLASPARAGINYLLEUCYLASPARAGINYLLEUCINE; TYROSYLLEUCYLSERYLGLYCYLALANYLASPARTYLLEUCYLASPARAGINYLLEUCINE; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL STIMULATION; CELL STRAIN COS1; CONTROLLED STUDY; CROSS REACTION; CYTOKINE RELEASE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOGENICITY; IRRADIATION; LYMPHOCYTE FUNCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

CARCINOEMBRYONIC ANTIGEN; CROSS REACTIONS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; INTERLEUKIN-7; NEOPLASMS; OLIGOPEPTIDES; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES;

EID: 34247122665     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31802b5005     Document Type: Article

References (38)

1. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature. 2001;411:380-384.
2. Evavold BD, Williams SG, Hsu BL, et al. Complete dissection of the Hb(64-76) determinant using T helper 1, T helper 2 clones, and T cell hybridomas. J Immunol. 1992;148:347-353.
3. Ruppert J, Sidney J, Celis E, et al. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 1993;74:929-937.
4. Loftus DJ, Squarcina P, Nielsen MB, et al. Peptides derived from self-proteins as partial agonists and antagonists of human CD8(+) T-cell clones reactive to melanoma/melanocyte epitope MART1(27-35). Cancer Res. 1998;58:2433.
5. Parkhurst MR, Salgaller ML, Southwood S, et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol. 1996;157:2539.
6. Vertuani S, Sette A, Sidney J, et al. Improved immunogenicity of an immunodominant epitope of the Her-2/neu protooncogene by alterations of MHC contact residues. J Immunol. 2004;172:3501.
7. Bownds S, Tong-On P, Rosenberg SA, et al. Induction of tumor-reactive cytotoxic T-lymphocytes using a peptide from NY-ESO-1 modified at the carboxy-terminus to enhance HLA-A2.1 binding affinity and stability in solution. J Immunother. 2001;24:1.
8. Valmori D, Levy F, Miconnet I, et al. Induction of potent antitumor CTL responses by recombinant vaccinia encoding a Melan-A peptide analogue. J Immunol. 2000;164:1125.
9. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med. 1998;4:321.
10. Kittlesen DJ, Thompson LW, Gulden PH, et al. Human melanoma patients recognize an HLA-A1-restricted CTL epitope from tyrosinase containing two cysteine residues: implications for tumor vaccine development (vol 160, pg 2099, 1998). J Immunol. 1999;162:3106.
11. Colella TA, Bullock TN, Russell LB, et al. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. J Exp Med. 2000;191:1221.
12. Sette A, Fikes J. Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. Curr Opinion Immunol. 2003;15:461.
13. Disis ML, Shiota FM, Cheever MA. Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for 'self' tumour antigens. Immunology. 1998;93:192.
14. Castilleja A, Carter D, Efferson CL, et al. Induction of tumor-reactive CTL by C-side chain variants of the CTL epitope HER-2/ neu protooncogene (369-377) selected by molecular modeling of the peptide: HLA-A2 complex. J Immunol. 2002;169:3545.
15. Rivoltini L, Squarcina P, Loftus DJ, et al. A superagonist variant of peptide MART1/Melan A27-35 elicits anti-melanoma CD8+ T cells with enhanced functional characteristics: implication for more effective immunotherapy. Cancer Res. 1999;59:301.
16. Tangri S, Ishioka GY, Huang XQ, et al. Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide. J Exp Med. 2001;194:833.
17. Fong L, Brockstedt D, Benike C, et al. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol. 2001;167:7150-7156.
18. Zaremba S, Barzaga E, Zhu MZ, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997;57:4570.
19. Gold P, Freedman SO. Specific carcinoembryonic antigens of the human digestive system. J Exp Med. 1965;122:467-481.
20. Graham RA, Wang S, Catalano PJ, et al. Postsurgical surveillance of colon cancer: preliminary cost analysis of physician examination, carcinoembryonic antigen testing, chest x-ray, and colonoscopy. Ann Surg. 1998;228:59-63.
21. Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol. 1999;9:67-81.
22. Thomson DM, Krupey J, Freedman SO, et al. The radioimmunoassay of circulating carcinoembryonic antigen of the human digestive system. Proc Natl Acad Sci U S A. 1969;64:161-167.
23. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106-130.
24. Tsang KY, Zaremba S, Nieroda CA, et al. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J Natl Cancer Inst. 1995;87:982-990.
25. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24:363-373.
26. Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A. 2003;100:4712-4717.
27. Kozak M. The scanning model for translation: an update. J Cell Biol. 1989;108:229-241.
28. Roszkowski JJ, Yu DC, Rubinstein MP, et al. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell. J Immunol. 2003;170:2582-2589.
29. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods. 1990;128:189-201.
30. Geysen HM, Rodda SJ, Mason TJ, et al. Strategies for epitope analysis using peptide synthesis. J Immunol Methods. 1987;102:259-274.
31. Leggatt GR, Hosmalin A, Pendleton CD, et al. The importance of pairwise interactions between peptide residues in the delineation of TCR specificity. J Immunol. 1998;161:4728-4735.
32. Yang S, Hodge JW, Grosenbach DW, et al. Vaccines with enhanced costimulation maintain high avidity memory CTL. J Immunol. 2005;175:3715-3723.
33. Schmitz J, Reali E, Hodge JW, et al. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. 2002;62:5058-5064.
34. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and- boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol. 2000;18:3964-3973.
35. Yu P, Lee Y, Liu W, et al. Priming of naive T cells inside tumors leads to eradication of established tumors. Nat Immunol. 2004;5:141-149.
36. Bunt SK, Sinha P, Clements VK, et al. Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression. J Immunol. 2006;176:284-290.
37. Munn DH, Sharma MD, Hou D, et al. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest. 2004;114:280-290.
38. Rodriguez PC, Quiceno DG, Zabaleta J, et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 2004;64:5839-5849.